Rekah Pharmaceutical Industry Ltd
TASE:REKA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 167
1 679
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one REKA stock under the Base Case scenario is 2 330.53 ILS. Compared to the current market price of 1 373 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Rekah Pharmaceutical Industry Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for REKA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Rekah Pharmaceutical Industry Ltd
Balance Sheet Decomposition
Rekah Pharmaceutical Industry Ltd
Current Assets | 225m |
Cash & Short-Term Investments | 5.4m |
Receivables | 120.2m |
Other Current Assets | 99.4m |
Non-Current Assets | 226.8m |
Long-Term Investments | 1.2m |
PP&E | 148.3m |
Intangibles | 63.7m |
Other Non-Current Assets | 13.7m |
Current Liabilities | 151m |
Accounts Payable | 111.8m |
Short-Term Debt | 22.4m |
Other Current Liabilities | 16.8m |
Non-Current Liabilities | 131.7m |
Long-Term Debt | 101.8m |
Other Non-Current Liabilities | 29.9m |
Earnings Waterfall
Rekah Pharmaceutical Industry Ltd
Revenue
|
324.4m
ILS
|
Cost of Revenue
|
-248.9m
ILS
|
Gross Profit
|
75.4m
ILS
|
Operating Expenses
|
-57.3m
ILS
|
Operating Income
|
18.1m
ILS
|
Other Expenses
|
-11.3m
ILS
|
Net Income
|
6.8m
ILS
|
Free Cash Flow Analysis
Rekah Pharmaceutical Industry Ltd
ILS | |
Free Cash Flow | ILS |
REKA Profitability Score
Profitability Due Diligence
Rekah Pharmaceutical Industry Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Rekah Pharmaceutical Industry Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
REKA Solvency Score
Solvency Due Diligence
Rekah Pharmaceutical Industry Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Rekah Pharmaceutical Industry Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
REKA Price Targets Summary
Rekah Pharmaceutical Industry Ltd
Dividends
Current shareholder yield for REKA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Contact
IPO
Employees
Officers
The intrinsic value of one REKA stock under the Base Case scenario is 2 330.53 ILS.
Compared to the current market price of 1 373 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 41%.